Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BWV-101
- Development stage
- Preclinical
- Lead developer
- Onconetix
- Modality
- Vaccines & Immunotherapeutics
01
Overview
BWV-101 is a universal influenza vaccine candidate under development by Blue Water Vaccines. It is designed as a prophylactic vaccine to provide broad protection against various strains of the influenza virus. The vaccine aims to address the limitations of current seasonal flu vaccines by targeting conserved regions of the virus, potentially offering broader and longer-lasting immunity. Development efforts involve collaboration with Instituto Butantan in Brazil, supported by grants from research foundations and partnerships with academic institutions such as the University of Oxford[2][3]. As of now, BWV-101 remains in preclinical development[3][4].
Beyond the preview
Go deeper on BWV-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BWV-101.